RECENT NEWS
Relay Drug Shows Early Promise against Rare Blood Vessel Diseases
Relay Therapeutics reported early clinical trial results showing its targeted therapy drug shrank tumors in patients with rare blood vessel cancers. The Silicon Review reports on the promising data for malignant peripheral nerve sheath tumors. Relay Therapeutics announced early clinical trial results showing its targeted therapy drug RLY-2608 demonstrated tumor shrinkage in patients with rare blood vessel cancers known as malignant peripheral nerve sheath tumors. The data was presented at the American Society of Clinical Oncology annual meeting. The targeted therapy drugs represent a new class of precision medicine that attacks cancer cells with specific genetic mutations while sparing healthy tissue. RLY-2608 is designed to inhibit the PI3K-alpha pathway, which is overactive in approximately 30 percent of MPNST patients. The new drug clinical trials enrolled 42 patients with advanced MPNST who had failed at least two prior lines of therapy. Results showed that 15 patients, or 36 percent, achieved partial remission with tumor shrinkage of at least 30 percent. Another 18 patients, or 43 percent, achieved stable disease. The median progression-free survival was 7.2 months. The ra...
Latest News and Business Magazines
